BPC-157
- Status
- Preclinical, , not approved for human use
- Evidence
Small human reports, abstract-only trials, graded on 4 research benches
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a partial sequence of human gastric juice protein BPC.
Reviewed
01Overview
What BPC-157 is
It has a molecular weight of 1419.53 Da and a CAS number of 137525-51-0. BPC-157 is classified as a stable gastric pentadecapeptide because it resists hydrolysis by gastric acid and digestive enzymes, a property that differentiates it from most bioactive peptides. That stability does not establish oral bioavailability: FDA's 2026 review found the absolute bioavailability of BPC-157 by mouth unknown in rats and dogs, and no information on its pharmacokinetics in people.
Read the full overviewShow less
As of 27 October 2026, a PubMed search for BPC-157 in the title or abstract returns 224 records, 172 of them with Predrag Sikiric as an author and 156 indexed with the MeSH term Animals. The records cover models of gastrointestinal injury, tendon and ligament damage, nerve injury, wound healing, and organ protection. A complete review by Sikiric et al. (2011) established BPC-157 as a peptide with broad cytoprotective and regenerative properties across multiple organ systems. Subsequent work by Seiwerth et al. (2022) expanded the evidence base to include vascular protection and modulation of the nitric oxide (NO) system as a central integrative mechanism.
BPC-157 is not approved by the United States Food and Drug Administration (FDA) for any therapeutic indication. It is classified under the World Anti-Doping Agency (WADA) Prohibited List category S0 (non-approved substances), making it banned in competitive sport. Despite the lack of regulatory approval, BPC-157 is widely used in the research peptide and biohacking communities, primarily administered via subcutaneous injection or oral capsule for musculoskeletal recovery and gut healing. In April 2026 FDA took BPC-157 off its Category 2 list of compounding substances that may present significant safety risks, after the nominations were withdrawn. In July 2026 an FDA advisory committee voted, against the advice of FDA staff, to recommend adding it to the 503A bulks list of substances pharmacies may compound from. Neither step is an approval. On 28 October 2026 HHS announced a draft interim policy covering BPC-157 acetate for subcutaneous, intramuscular, oral or topical use. Under it, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound it under set conditions, including a single active ingredient per product, so a BPC-157 and TB-500 blend is not covered. The policy is not an approval and does not add BPC-157 to the bulks list.
Preclinical studies have demonstrated that BPC-157 accelerates healing of transected rat Achilles tendons, with treated animals showing superior biomechanical tendon strength at 14 days post-injury compared to controls (PMID: 14554208). In gastrointestinal models, BPC-157 has shown protective effects against NSAID-induced gastric lesions, ethanol-induced mucosal damage, and inflammatory bowel disease (IBD) analogs including experimentally induced colitis. The peptide has also demonstrated neuroprotective activity in dopaminergic and serotonergic systems, counteracting lesions caused by neurotoxins in rodent models.
A 2025 pilot safety study by Lee et al. represents the first published human intravenous (IV) administration data for BPC-157. Two adults who had both received intravenous BPC-157 before were given 10 mg on day 1 and 20 mg on day 2; no side effects were reported and their heart, liver, kidney, thyroid and blood glucose markers did not change (PMID: 40131143). With two participants and no control group, the study cannot establish safety, and it was not the first human safety study. FDA's 2026 review lists a placebo-controlled phase 1 enema study in healthy volunteers, known only from 2002 and 2003 meeting abstracts, in which 24 of 32 randomized subjects received BPC-157; headache and flatulence, the most frequent adverse events, showed no clear difference from placebo.
BPC-157 has also been shown to upregulate growth hormone receptor (GHR) expression in tendon fibroblasts cultured from rat Achilles tendon, where added growth hormone then raised cell proliferation (PMID: 25415472); no study has given BPC-157 together with a growth hormone secretagogue. The peptide is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Lyophilized BPC-157 should be stored at -20 degrees Celsius in a desiccated environment; once reconstituted, it should be refrigerated at 2-8 degrees Celsius and used within 28 days to maintain peptide integrity.
How it works
Nitric Oxide (NO) System Modulation
BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a stabilizer of the NO system rather than a simple agonist or antagonist. This bidirectional NO modulation is proposed as the mechanism underlying BPC-157's ability to protect against diverse insults including ischemia-reperfusion injury, endothelial dysfunction, and vasospasm. BPC-157 interacts with the eNOS pathway, maintaining vascular homeostasis and supporting angiogenesis in damaged tissues.
Read the full mechanismShow less
VEGFR2 and Angiogenesis Pathway
BPC-157 significantly upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression in injured tissues. This leads to enhanced angiogenesis — the formation of new blood vessels — which is critical for tissue repair in tendons, ligaments, muscle, and gastrointestinal mucosa. In rat tendon transection models, BPC-157-treated animals exhibited greater capillary density at the repair site at 14 days post-injury. The pro-angiogenic effect operates through VEGF-VEGFR2-mediated endothelial cell proliferation and tube formation.
EGR-1 Transcription Factor and FAK-Paxillin Signaling
BPC-157 stimulates early growth response gene 1 (EGR-1), a transcription factor involved in wound healing, cell proliferation, and differentiation. EGR-1 activation leads to downstream upregulation of cytokines and growth factors critical for tissue remodeling. Additionally, BPC-157 activates the focal adhesion kinase (FAK)-paxillin pathway, which governs cell adhesion, migration, and extracellular matrix reorganization. This signaling cascade is particularly important in tendon healing, where collagen fiber realignment depends on mechanotransduction signaling through focal adhesions.
Growth Hormone Receptor Upregulation
BPC-157 has been demonstrated to upregulate growth hormone receptor (GHR) expression in tendon fibroblasts cultured from rat Achilles tendon (PMID: 25415472). This finding suggests that BPC-157 may potentiate the local effects of circulating growth hormone and IGF-1, improving tissue repair capacity beyond what the peptide achieves through its direct signaling pathways. No study has given BPC-157 together with a growth hormone secretagogue such as ipamorelin or CJC-1295, so any synergy between them is untested.
Neuroprotective Mechanisms
BPC-157 interacts with the dopaminergic and serotonergic neurotransmitter systems. In rodent models of neurotoxin-induced dopaminergic lesions (analogous to Parkinson's disease), BPC-157 provided significant neuroprotection, maintaining dopaminergic neuron viability and motor function. The peptide also modulates serotonin turnover, exerting antidepressant-like and anxiolytic-like effects in behavioral testing paradigms. These central nervous system effects are thought to be mediated through GABAergic modulation and direct interaction with dopamine transporter and receptor expression.
Studied for
- Wound healing
- Gastric ulcers
- Tendinopathy
- Neuroprotection
- IBD
Benefits listed
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
Show 4 moreShow less
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
02Research
Free with emailWhat the research shows
Graded on 4 research benches
Reference pages that put BPC-157 next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
- Tissue Repair BenchSmall human reports, abstract-only trialshuman data on 3 of 6 compounds on the bench
- Peptides for Gut HealthSmall human reports, abstract-only trialshuman data on 4 of 5 compounds on the bench
- Wolverine StackSmall human reports, abstract-only trialshuman data on 2 of 4 compounds on the bench
- Anti-Inflammatory SupplementsSmall human reports, abstract-only trialshuman data on 5 of 6 compounds on the bench
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
BPC-157 side effects and interactions
Side effects
Common
- Injection site redness or mild irritation (subcutaneous)
- Mild nausea with oral administration (rare)
- Transient lightheadedness reported anecdotally
Serious events
- No adverse events reported in a 2-person intravenous pilot study (PMID: 40131143)
- A single intramuscular dose of 20 mg/kg in rats and 10 mg/kg in dogs caused no signs of acute toxicity (PMID: 32334036); FDA's 2026 review found no acute toxicity study by the nominated routes (oral, rectal, subcutaneous and nasal), and no lethal dose has been established
- The authors of 28-day intramuscular studies in rats and dogs reported no organ damage, but FDA's 2026 review of those studies noted altered clotting times (aPTT) and liver-related signals, including higher serum ALT (PMID: 32334036)
Who should not use it
Contraindications
Active cancer or history of cancer (due to angiogenic properties). Pregnancy or breastfeeding. Concurrent use of anticoagulants (may affect platelet function). Caution in patients with active infections where increased blood flow could spread pathogens.
Interactions
6 pairings in our record: 4 with a caution and 2 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
TB-500
CautionCommonly paired, but the one controlled study of the pair, in rats with repaired Achilles tendons, found no added benefit over either peptide alone (PMID: 42542926). FDA's adverse event database also holds a report of skin and gum darkening, recurring on rechallenge, with a research product containing both.
GHK-Cu
CautionNo study has tested BPC-157 and GHK-Cu together, so any added benefit is unmeasured.
NSAIDs
CautionNo study has tested whether BPC-157 reduces the need for NSAIDs; the NSAID work is in rats, where BPC-157 reduced stomach and gut lesions caused by high NSAID doses. Monitor for GI effects if combining.
IGF-1 LR3
CautionBoth promote growth factor activity — use conservative doses when stacking
MK-677
CompatibleGH elevation from MK-677 may complement BPC-157 tissue repair
LL-37
CompatibleLL-37 antimicrobial action complements BPC-157 tissue repair in wound healing
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailBPC-157 dosage and protocols
- Dose range
- 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies
- Dosing
- Twice daily (AM and PM), an empirical schedule not derived from serum levels; once daily acceptable
- Common vials
- 5mg, 10mg
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
BPC-157 prices
15 listings from 7 vendors, opening in the Featured order.
- Pack prices
- $34.99 to $79.99
- Lowest per mg
- $2.33/mg
- Vendors
- 7
- Listings
- 15 (vial, capsule)
Prices as the vendors list them, last recorded 18 November 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
BPC-157 Capsules capsule, 60 caps (500mcg each) In stock | $2.67/mg $79.99 | Buy BPC-157 Capsules at ResearchChemHQ | |
BPC-157 500mcg, 60 Dry-Fill Units capsule, 60 dry-fill units In stock | $2.33/mg $69.99 Lowest per mg | Buy BPC-157 500mcg, 60 Dry-Fill Units at BHG Labs | |
BPC-157 10mg vial, 5mg In stock | $3.80/mg $37.99 | Buy BPC-157 10mg at Optimum Formula | |
BPC-157 500mcg Capsules (60 ct, oral) capsule, 60 capsules - 500mcg each In stock | $2.67/mg $79.99 | Buy BPC-157 500mcg Capsules (60 ct, oral) at Optimum Formula | |
BPC-157 5mg vial, 1 vial Out of stock | $5.80/mg $29.00 | View BPC-157 5mg at Ion Peptide | |
BPC-157 10mg vial, 1 vial In stock | $4.80/mg $48.00 | Buy BPC-157 10mg at Ion Peptide | |
BPC-157 20mg vial, 1 vial Out of stock | $4.25/mg $85.00 | View BPC-157 20mg at Ion Peptide | |
BPC-157 5mg vial, 1 vial In stock | $7.00/mg $34.99 | Buy BPC-157 5mg at BioMyst Labs | |
BPC-157 5mg vial, 1 vial In stock | $7.00/mg $34.99 | Buy BPC-157 5mg at BioMyst Labs | |
BPC-157 10mg vial, 1 vial In stock | $5.50/mg $54.99 | Buy BPC-157 10mg at BioMyst Labs | |
BPC-157 10mg vial, 1 vial In stock | $5.53/mg $55.25 | Buy BPC-157 10mg at BioMyst Labs | |
BPC-157 10mg vial, 1 vial Out of stock | $5.35/mg $53.50 | View BPC-157 10mg at Limitless Biochem EU | |
BPC-157/TB-500 5+5mg vial, 1 vial In stock | $6.96/mg $69.55 | Buy BPC-157/TB-500 5+5mg at Limitless Biochem EU | |
BPC-157 5mg vial, 5mg vial In stock | $8.00/mg $39.99 | Buy BPC-157 5mg at Half Nattys | |
BPC-157 10mg vial, 10mg vial In stock | $5.50/mg $54.99 | Buy BPC-157 10mg at Half Nattys |
Vendors selling BPC-157(7: trust score, certificates, payment, shipping)
- Ion Peptide3 listings, from $29.00
Trust Score 70/100, no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations
- BioMyst Labs4 listings, from $34.99
Trust Score 70/100, no certificate records on file, pays by card, crypto, ships to the US, international destinations
- Optimum Formula2 listings, from $37.99
Trust Score 100/100, 4 of 6 certificate records read, pays by card, crypto, ships to the US
- Half Nattys2 listings, from $39.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- Limitless Biochem EU2 listings, from $53.50
Trust Score 70/100, no certificate records on file, pays by card, crypto, bank transfer, ships to the US, the EU, the UK, Australia
- BHG Labs1 listing, from $69.99
Trust Score 100/100, 41 of 43 certificate records read, pays by card, crypto, ships to the US
- ResearchChemHQ1 listing, from $79.99
Trust Score 100/100, 6 of 6 certificate records read, pays by card, crypto, ships to the US
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(11 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C62H98N16O22
- Molecular mass
- 1419.56 g/mol
- CAS number
- 137525-51-0
- IUPAC name
- glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
- Amino acid sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV); 15-amino-acid pentadecapeptide, a partial sequence of human gastric juice protein BPC
- Half-life
- Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.
08Questions
Frequently asked questions
What is BPC-157 used for in research?
BPC-157 is a synthetic peptide based on a sequence found in stomach protein. Most of the research looks at tissue repair, tendon and ligament healing, and gut protection. It is one of the most-studied recovery peptides.
How is BPC-157 dosed in research protocols?
Common research protocols use roughly 250 to 500 mcg per day subcutaneously, often near the area of interest. This site has a free reconstitution calculator that turns your vial size and target dose into exact syringe units.
BPC-157 vs TB-500: should you stack them?
They are frequently run together because they work through different mechanisms, BPC-157 more local and angiogenic, TB-500 more systemic. There is a full comparison and the popular 'Wolverine stack' protocol on the blog.
How many vendors sell BPC-157, and what does it cost per mg?
7 of the vendors BodyHackGuide tracks list BPC-157 (15 listings). Among BodyHackGuide's BPC-157 listings recorded as in stock with a milligram count, the lowest price per milligram is $2.33/mg at BHG Labs and the median is $5.50/mg. The BPC-157 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a BPC-157 listing is dated 18 November 2026.
Which vendors have third-party COAs for BPC-157 on file at BodyHackGuide?
BodyHackGuide holds 299 third-party certificate records for BPC-157, from ResearchChemHQ and Optimum Formula and Half Nattys and BHG Labs and Disguised Alpha. An editor has read 3 of BodyHackGuide's 299 certificate records for BPC-157 and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's BPC-157 certificate records are Janoshik Analytical, Freedom Diagnostics Testing and ILS Laboratories, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on BPC-157
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.






